<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a 49-year-old female patient with secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> who developed <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> and <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> caused by low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment of low-dose Ara-C has widely been used for <z:hpo ids='HP_0011009'>acute</z:hpo> myelogeous <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and it is thought to be a low toxicity except for <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The patient complained of a transient adverse reaction in the second and third course of therapy </plain></SENT>
<SENT sid="3" pm="."><plain>This rare case indicates that careful observation should be carried out during low-dose Ara-C therapy in view of allergic reactions </plain></SENT>
</text></document>